| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 93.336 | 95.859 | 104.929 | 114.100 | 120.406 | 149.796 | 132.712 | 150.968 | 159.207 | 164.035 |
| Total Income - EUR | 93.342 | 95.864 | 104.935 | 114.105 | 120.412 | 149.805 | 132.724 | 150.981 | 159.274 | 164.050 |
| Total Expenses - EUR | 87.160 | 92.427 | 99.689 | 104.574 | 108.953 | 130.701 | 117.739 | 133.654 | 143.757 | 153.233 |
| Gross Profit/Loss - EUR | 6.182 | 3.437 | 5.246 | 9.531 | 11.459 | 19.104 | 14.985 | 17.327 | 15.517 | 10.817 |
| Net Profit/Loss - EUR | 5.193 | 2.478 | 4.197 | 8.390 | 10.255 | 17.680 | 13.658 | 15.817 | 13.965 | 9.121 |
| Employees | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
Check the financial reports for the company - Silvapharm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 10.052 | 6.776 | 3.613 | 722 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 60.659 | 36.274 | 34.851 | 46.111 | 46.223 | 52.613 | 58.663 | 50.123 | 55.997 | 49.880 |
| Inventories | 18.599 | 18.724 | 17.608 | 15.571 | 15.284 | 17.931 | 16.341 | 18.049 | 19.622 | 21.699 |
| Receivables | 8.537 | 2.416 | 10.799 | 14.748 | 12.628 | 17.969 | 14.880 | 17.286 | 15.308 | 10.657 |
| Cash | 33.523 | 15.133 | 6.444 | 15.792 | 18.311 | 16.713 | 27.443 | 14.788 | 21.068 | 17.525 |
| Shareholders Funds | 42.759 | 2.523 | 4.240 | 8.433 | 10.297 | 17.721 | 20.474 | 24.188 | 23.928 | 17.637 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 27.953 | 40.527 | 34.224 | 38.399 | 35.926 | 34.891 | 38.189 | 25.935 | 32.069 | 32.243 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Silvapharm S.r.l.